Ask what a GLP-1 costs in the United States and you will get a number somewhere between forty dollars and thirteen hundred dollars a month, all of which are true, none of which are useful without knowing which of five separate prices is being quoted.
The five prices
1. List price
The manufacturer’s published price before any discount. It is the number in news coverage and the number almost nobody pays. For the branded weight-management products it has sat above a thousand dollars a month.
2. The negotiated price
What your insurer or PBM actually pays after rebates. It is confidential, materially lower than list, and you will never see it.
3. Your copay
What you pay at the counter if the drug is covered and you are approved. This is the number that matters to you, and it depends entirely on your plan’s formulary, your deductible status, and whether the indication is diabetes or obesity — which are treated very differently by most plans.
4. Manufacturer savings programs
Both major manufacturers run copay assistance and direct-to-consumer cash programs. These change frequently, carry eligibility restrictions, and are generally unavailable to anyone on Medicare or Medicaid — a restriction that surprises people every day.
5. Compounded pricing
The gray market, priced far below anything above, with a corresponding set of risks around sourcing, dosing accuracy, and legal status. We cover compounding separately, because it deserves more than a line in a pricing guide.
Why coverage for obesity is the hard part
The structural problem is a distinction most plans still draw between treating type 2 diabetes and treating obesity. The first is routinely covered. The second is frequently excluded outright, treated as a lifestyle benefit rather than a medical one.
This is why two people on chemically identical molecules can pay twenty-five dollars and eleven hundred dollars respectively.
Medicare’s position has been particularly consequential: a longstanding statutory exclusion on coverage of drugs used for weight loss has shaped the entire market, with coverage generally arriving only through an approved indication other than obesity itself — cardiovascular risk reduction, or obstructive sleep apnea.
If the answer turns out to be that a GLP-1 is out of reach, the licensed non-GLP-1 drugs are compared in Ozempic alternatives — and the supplement route, which is heavily marketed at exactly this problem, is assessed in the “natural Ozempic” question.
Before any of this, it is worth confirming you meet the licensed indication at all, since eligibility and coverage are separate questions that get conflated constantly — see do you qualify.
If you are trying to get it covered
The practical steps, in the order they usually matter:
- Get the formulary in writing. Not the summary — the actual drug list, with tier and restrictions. Your plan must provide it.
- Find out whether obesity is an excluded benefit. If it is excluded at the plan level, prior authorization will not help; you need a different clinical pathway or a different plan.
- Document the clinical history. Prior interventions, comorbidities, and measurements. Denials frequently turn on missing documentation rather than on judgment.
- Appeal. A meaningful share of initial denials are overturned. Most people never file.
- Ask about a separate indication. If you have sleep apnea or established cardiovascular disease, the coverage question may be a different question entirely.
Step three is where most people are weakest, and it is fixable in advance rather than in a panic. A dated record of dose, weight, blood pressure and side effects turns this treatment is working from an assertion into an attachment. Start it in the week you start the drug, not the week you are denied — Zenday or anything that will produce something you can export and hand over.
The most expensive thing about these drugs in America is not the molecule. It is the paperwork nobody tells you to file.
The employer question
A growing number of large employers have added, then narrowed, then re-added coverage for weight-management drugs — usually with requirements attached: BMI thresholds, participation in a lifestyle program, a fixed duration, or a step-therapy requirement.
If your coverage runs through an employer plan, the benefits team, not the pharmacy, is where the real answer lives.
The honest summary
There is no single American price for these medications, and the range between the best and worst outcome for two otherwise identical patients is roughly thirty-fold. That is not a market failure at the edges; it is the central fact of the system.
Which is why the most valuable hour you will spend on this is not researching molecules. It is on the phone with your plan.